Follow-up of Pediatric Patients Affected by Primary Hyperoxaluria Type 1 (PH1) Treated With Lumasiran

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The primary objective of the study is to confirm, in pediatric patients with type 1 hyperoxaluria treated with Lumasiran, the reduction in urinary oxalate excretion and plasma oxalate levels-already described at six months-on a larger number of patients and with an extended follow-up (1-5 years), and to evaluate in the same patients the ultrasound-detected reduction in the number of kidney stones over time from the initiation of treatment.
Epistemonikos ID: 50b4f82c97621c55c19da6ae2154b23ddc8dec6a
First added on: Oct 15, 2026